CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Lianhua QingwenWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug407 Bromhexine Hydrochloride Tablets Wiki 1.00
drug209 Arbidol Hydrochloride Granules Wiki 1.00
drug2037 Recombinant Human Interferon α2b Spray Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19

COVID-19 virus remains in infected patients for extended periods of time. A great resource burden is placed on the healthcare system and society at large to isolate COVID-19 patients for prolonged periods. Thus, being able to increase the rate of viral clearance, thus reducing the duration of COVID-19 infection, would allow patients to be discharged earlier to free up resources for those who require it. The investigators designed a randomized controlled trial, investigating the use of Lianhua Qingwen, a TCM treatment, in COVID-19 infected patients with mild symptoms. The investigators hypothesize that the use of Lianhua Qingwen will increase the proportion of patients who test negative for COVID-19 after 8 days of TCM treatment when compared to the group of patients provided with standard care and placebo. Patients will be recruited from community isolation facilities, and have onset of symptoms within 5 days prior to admission to the isolation facility. The trial also evaluates the time taken for relief of clinical symptoms associated with COVID-19 and assesses the safety of the TCM treatment given to patients.

NCT04433013 COVID-19 Drug: Lianhua Qingwen Drug: Placebo

Primary Outcomes

Measure: Proportion of participants who test negative for COVID-19

Time: after 8 days of treatment

Secondary Outcomes

Measure: Time taken in days for relief of clinical symptoms

Time: during the 8-day course of treatment

Measure: Proportion of participants with mild symptoms of COVID-19 progressing to moderate or severe illness

Time: after 8 days of treatment and at the end of the trial

Measure: Proportion of participants who test positive for COVID-19 with Ct value>30

Time: after 8 days of treatment

No related HPO nodes (Using clinical trials)